MedTrace Logo

Ground-Breaking Electroporation-based Intervention for PAROXysmal Atrial Fibrillation Treatment (BEAT PAROX-AF)

NCT05159492 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 292

Last updated 2026-05-14

No results posted yet for this study

Summary

BEAT AF is a randomized controlled trial aiming to demonstrate that pulsed field energy is faster, more effective and safer (tissue selectivity) than RF for paroxysmal AF ablation

Conditions

Interventions

DEVICE

PVI using PEF

PVI using PEF

DEVICE

PVI using CFRF

PVI using CFRF

Sponsors & Collaborators

  • Horizon 2020 - European Commission

    collaborator OTHER

  • University Hospital, Bordeaux

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-27
Primary Completion
2025-02-14
Completion
2025-02-14
FDA Device
Yes

Countries

  • Austria
  • Belgium
  • Czechia
  • France
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05159492 on ClinicalTrials.gov